LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2019 to Q3 2023

Type / Class
Debt / NOTE 0.750% 5/1
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 across Reporting Periods

Period Principal Value Change Price (% of par) (Median) Investors
2023 Q3 $0 $0 -$298,682 0
2023 Q2 $300,000 $298,682 -$71,020,895 99.56% 1
2023 Q1 $71,838,000 $71,319,577 +$5,274,286 99.27% 26
2022 Q4 $66,591,000 $65,027,776 -$3,765,173 97.31% 25
2022 Q3 $65,515,065 $63,620,509 -$33,301,456 96.98% 23
2022 Q2 $99,737,000 $96,520,000 -$63,868,614 96.25% 23
2022 Q1 $163,370,304 $159,551,350 -$147,074,042 97.68% 30
2021 Q4 $308,323,081 $309,277,880 -$3,639,868 100.15% 32
2021 Q3 $321,671,858 $323,960,305 -$848,378 100.39% 38
2021 Q2 $323,098,546 $319,930,461 -$15,166,559 98.85% 43
2021 Q1 $336,008,737 $348,627,573 -$134,181,176 103.55% 48
2020 Q4 $474,601,474 $451,327,177 -$23,135,199 94.84% 46
2020 Q3 $505,163,049 $458,227,307 +$27,473,180 90.57% 47
2020 Q2 $479,836,374 $423,793,862 -$14,928,946 87.6% 47
2020 Q1 $500,126,237 $418,687,950 -$191,611,306 82.81% 44
2019 Q4 $735,378,302 $636,640,277 -$20,703,526 86.55% 48
2019 Q3 $744,169,000 $621,973,473 +$15,191,167 83.43% 47
2019 Q2 $726,411,131 $626,631,807 +$621,342,068 86.32% 49